Category: Oncology
Talazoparib resistance in triple-negative breast cancer linked to BRN2 and SHLD2
—
in OncologyStudy identifies BRN2-mediated and SHLD2-related resistance to talazoparib in BRCA-mutant breast cancer, proposing combination therapy approaches to improve neoadjuvant treatment outcomes.
Olutasidenib showed disease control in conventional chondrosarcoma
—
in OncologyPhase 1b/2 trial of olutasidenib in IDH1-mutated chondrosarcoma shows disease control without dose-limiting toxicities; 52% stable disease rate in recurrent/metastatic disease.
Combination therapy showed a temporary response in metastatic DDCS
—
in OncologyCase report demonstrates promising response to pembrolizumab and pazopanib combination therapy in metastatic dedifferentiated chondrosarcoma, highlighting emerging systemic treatment options.
FMT with immunotherapy showed activity in NSCLC and melanoma
—
in OncologyPhase 2 trial: donor FMT plus first-line ICI in NSCLC and melanoma showed high ORRs and implicates loss of specific bacterial taxa in association with response.
